Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Talzenna (talazoparib by Year
Talzenna (talazoparib — PARP inhibitor) — Worldwide revenues ($M) ($M)
Pfizer Talzenna (talazoparib: $182M in FY2025, up 55.6% from a year earlier.
Where the FY2025 figure comes from
“|| Talzenna | 182 | 117 | 55% | 54% | 133 | 88 | 51% | 50 | 30 | 67% | 63%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Talzenna (talazoparib — PARP inhibitor) — Worldwide revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 182 | +55.6% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 117 | +82.8% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 64 | +33.3% | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 48 | – | Form 10-K (filed 2025-02-27) ↗ |
Breakdown
What makes up talzenna (talazoparib
- Talzenna (talazoparib — PARP inhibitor) — U.S. revenues ($M)133 · FY2025
- Talzenna (talazoparib — PARP inhibitor) — International revenues ($M)50 · FY2025
- Talzenna (talazoparib — PARP inhibitor) — Worldwide reported YoY (%)55.0% · FY2025
- Talzenna (talazoparib — PARP inhibitor) — Worldwide operational (constant-currency) YoY (%)54.0% · FY2025
Cite this data
StockData. (2026). Pfizer Talzenna (talazoparib ($M), annual FY2022–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/talzenna-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.